Diabetes

Approximately 37.1 million adults in the U.S. are living with diabetes, although 1 in 5 are not aware of their condition. Type 2 diabetes is a chronic, progressive condition that accounts for 90-95% of all cases and is a leading cause of death in the U.S.

Diabetes can also increase the risk of developing associated cardio-renal-metabolic (C-R-M) conditions, including heart failure and chronic kidney disease. C-R-M conditions are a group of interconnected disorders that affect more than 1 billion people worldwide and account for up to 20 million deaths annually in the U.S. The cardiovascular, renal (kidney) and metabolic systems are intricately linked and share many of the same disease-related pathways. Dysfunction in one system may accelerate the onset of dysfunction in others, resulting in the progression of comorbid diseases such as type 2 diabetes, heart failure and chronic kidney disease. Conversely, improving the health of one system can lead to positive effects across the others and can help reduce risk for further complications.

A greater understanding of C-R-M conditions and the treatments that help restore harmony between these systems has ushered in a new era of diabetes care. Guideline updates and professional organizations such as the American Diabetes Association reflect the need to prioritize multidisciplinary management of people with type 2 diabetes.

Through research and educational initiatives, Boehringer Ingelheim, with our partner Eli Lilly and Company, is working to advance treatments that can treat conditions of the C-R-M systems and help redefine care for people living with these conditions.